SAN DIEGO, May 31, 2011 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the
Goldman Sachs 32nd Annual Global Healthcare Conference on
Tuesday, June 7, 2011, at
12:20 p.m. ET / 9:20 a.m. PT in Palos
Verdes, California and at the
Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00
a.m. PT in New York. Daniel
M. Bradbury, president and chief
executive officer of Amylin Pharmaceuticals, will provide a
corporate overview at the Goldman Sachs conference. Mark
Foletta, senior vice president, finance and chief financial officer
of Amylin, will provide a corporate overview at the Jeffries
conference.
The presentations will be webcast live through the "Investors"
section of Amylin's corporate website at www.amylin.com, and the
recordings will be made available on the website following the
events. To access the live webcasts, please log on to Amylin's
website approximately fifteen minutes prior to the presentations to
register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information about Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.